Because massive re-replication can drive cell death specifically in checkpoint-compromised cancer cells, both CDT1 stabilization by inactivation of ubiquitin-mediated degradation and inhibition of DOT1L are currently being explored as novel anti-cancer therapeutic strategies25–31. The gene discussed is DOT1L; the disease is cancer.